Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks

Executive Summary

In an analysis of direct-to-consumer mobile promotions, FDA found that risks and benefits are not equally prominent and accessible in the communications and their landing pages.

Advertisement

Related Content

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel